Kelyniam Global, Inc. Receives FDA Clearance for Innovative Fusion™ BCP-PEEK Implant
Rhea-AI Summary
Kelyniam Global (KLYG) has achieved a significant milestone with FDA 510(k) clearance for its innovative Fusion™ Cranial and Craniofacial Implants. The implants utilize a groundbreaking combination of Biphasic Calcium Phosphate (BCP) reinforced with Polyether Ether Ketone (PEEK), marking the first FDA approval for this material in cranial implants.
The Fusion™ BCP-PEEK implant represents the first new implant in the cranial market in 8 years. The company can design, manufacture, and ship these custom implants within 24-48 hours. The technology is designed to promote bone integration while maintaining durability and personalized fit, complementing Kelyniam's existing regenerative product portfolio.
Positive
- First FDA-approved BCP-PEEK material for cranial implants in the US
- First new implant in cranial/craniofacial market in 8 years
- Rapid 24-48 hour manufacturing and shipping capability
- Enhanced bone integration properties while maintaining durability
Negative
- None.
News Market Reaction – KLYG
In the Sep 18 session, KLYG gained 40.91%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
This 510(k) clearance marks the first time the FDA has approved this material for use in cranial and craniofacial implants, representing a significant milestone in implant technology. The Fusion™ BCP-PEEK implant is the first totally new implant launched in the cranial and craniofacial market in 8 years.
"Kelyniam's achievement as the first company in the
Designed for custom applications , the Fusion™ BCP-PEEK material meets critical neurosurgery needs where precise, patient-specific solutions are essential for treating traumatic injuries, defects from tumor resections, or congenital anomalies. As with Kelyniam's PEEK implants, Fusion™ BCP-PEEK custom implants can be designed, manufactured and shipped to surgeons within 24-48 hours, ensuring timely care for patients in need.
Ross Bjella, Chairman and CEO, added, "Kelyniam continues to deliver cutting-edge technology to neurosurgeons. This unique implant is an important part of our regenerative product line, which includes our CustomizedBone™ (hydroxyapatite) implant from Finceramica, SpA, and the Osteopore range of products."
About Kelyniam Global, Inc. Kelyniam Global, Inc. specializes in rapidly producing custom cranial and craniofacial implants using biocompatible materials. By partnering with neurosurgeons worldwide, the company delivers high-quality, patient-specific solutions with a quick turnaround time. Dedicated to innovation in regenerative medicine, Kelyniam continues to enhance neurosurgical care. For more information, visit www.kelyniam.com .
Forward-Looking Statements This press release contains forward-looking statements under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve risks and uncertainties that may cause actual results to differ from projections. Investors should not place undue reliance on these forward-looking statements.